There are several anti-EGFR monoclonal antibodies developed for targeting human epithelial cancers of which at least five have been evaluated in clinical trials as potential EGFR-targeted therapy for HNSCC patients [36]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.